{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:04:11Z","timestamp":1742969051515,"version":"3.40.3"},"publisher-location":"Dordrecht","reference-count":76,"publisher":"Springer Netherlands","isbn-type":[{"type":"print","value":"9789400775688"},{"type":"electronic","value":"9789400775695"}],"license":[{"start":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T00:00:00Z","timestamp":1381449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-94-007-7569-5_12","type":"book-chapter","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T16:21:20Z","timestamp":1384359680000},"page":"235-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Targeted Therapies for Bone Metastases"],"prefix":"10.1007","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Sieber","sequence":"additional","affiliation":[]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,10,11]]},"reference":[{"key":"12_CR1","unstructured":"(2012) Amgen XGEVA [denosumab] prescribing information. Amgen, Thousand Oaks"},{"issue":"3","key":"12_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/SPC.0b013e32830baac2","volume":"2","author":"A Lipton","year":"2008","unstructured":"Lipton A, Jun S (2008) RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2(3):197\u2013203","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"12_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","volume":"18","author":"WC Dougall","year":"2012","unstructured":"Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18(2):326\u2013335","journal-title":"Clin Cancer Res"},{"issue":"16","key":"12_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655\u20131664","journal-title":"N Engl J Med"},{"issue":"8","key":"12_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584\u2013593","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"12_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.1199","volume":"198","author":"S Kitazawa","year":"2002","unstructured":"Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228\u2013236","journal-title":"J Pathol"},{"issue":"1","key":"12_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eururo.2003.10.003","volume":"45","author":"F Saad","year":"2004","unstructured":"Saad F, Schulman CC (2004) Role of bisphosphonates in prostate cancer. Eur Urol 45(1):26\u201334","journal-title":"Eur Urol"},{"issue":"19","key":"12_CR8","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.1830978100","volume":"100","author":"JJ Yin","year":"2003","unstructured":"Yin JJ, Mohammad KS, Kakonen SM et al (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100(19):10954\u201310959","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"12_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165\u2013176","journal-title":"Cell"},{"issue":"1","key":"12_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/pros.20678","volume":"68","author":"AP Armstrong","year":"2008","unstructured":"Armstrong AP, Miller RE, Jones JC et al (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1):92\u2013104","journal-title":"Prostate"},{"issue":"2","key":"12_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2):119\u2013129","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"12_CR12","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1158\/0008-5472.CAN-12-0044","volume":"72","author":"M Palafox","year":"2012","unstructured":"Palafox M, Ferrer I, Pellegrini P et al (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72(11):2879\u20132888","journal-title":"Cancer Res"},{"issue":"4","key":"12_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bone.2006.11.006","volume":"40","author":"K Mori","year":"2007","unstructured":"Mori K, Le Goff B, Charrier C et al (2007) DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40(4):981\u2013990","journal-title":"Bone"},{"issue":"35","key":"12_CR14","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132\u20135139","journal-title":"J Clin Oncol"},{"issue":"9768","key":"12_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822","journal-title":"Lancet"},{"issue":"9","key":"12_CR16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125\u20131132","journal-title":"J Clin Oncol"},{"issue":"16","key":"12_CR17","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT et al (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092","journal-title":"Eur J Cancer"},{"issue":"9810","key":"12_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810):39\u201346","journal-title":"Lancet"},{"key":"12_CR19","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Shore ND et al (2012) Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 30 (5_suppl):abstr 6 (February 10 Supplement)","DOI":"10.1200\/jco.2012.30.5_suppl.6"},{"issue":"1\u20132","key":"12_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mce.2011.09.030","volume":"357","author":"R Fernandez-Valdivia","year":"2012","unstructured":"Fernandez-Valdivia R, Lydon JP (2012) From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol 357(1\u20132):91\u2013100","journal-title":"Mol Cell Endocrinol"},{"issue":"suppl 9","key":"12_CR21","doi-asserted-by":"publisher","first-page":"ix95","DOI":"10.1093\/annonc\/mds392","volume":"23","author":"RE Coleman","year":"2012","unstructured":"Coleman RE, Barrios C, Bell R et al (2012) Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an in-progress, phase 3 clinical trial. Ann Oncol 23(suppl 9):ix95\u2013ix115","journal-title":"Ann Oncol"},{"issue":"7","key":"12_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/bies.950190709","volume":"19","author":"A Alevizopoulos","year":"1997","unstructured":"Alevizopoulos A, Mermod N (1997) Transforming growth factor-beta: the breaking open of a black box. Bioessays 19(7):581\u2013591","journal-title":"Bioessays"},{"issue":"15","key":"12_CR23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1286-4579(99)00251-8","volume":"1","author":"M Reiss","year":"1999","unstructured":"Reiss M (1999) TGF-beta and cancer. Microbes Infect 1(15):1327\u20131347","journal-title":"Microbes Infect"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2741\/1606","volume":"10","author":"S Narayan","year":"2005","unstructured":"Narayan S, Thangasamy T, Balusu R (2005) Transforming growth factor -beta receptor signaling in cancer. Front Biosci 10:1135\u20131145","journal-title":"Front Biosci"},{"issue":"9","key":"12_CR25","first-page":"2210","volume":"59","author":"S Ananth","year":"1999","unstructured":"Ananth S, Knebelmann B, Gruning W et al (1999) Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59(9):2210\u20132216","journal-title":"Cancer Res"},{"issue":"12","key":"12_CR26","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.4049\/jimmunol.1003816","volume":"186","author":"C Penafuerte","year":"2011","unstructured":"Penafuerte C, Bautista-Lopez N, Bouchentouf M et al (2011) Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 186(12):6933\u20136944","journal-title":"J Immunol"},{"issue":"4","key":"12_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/1535-7163.MCT-07-0337","volume":"7","author":"D Melisi","year":"2008","unstructured":"Melisi D, Ishiyama S, Sclabas GM et al (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7(4):829\u2013840","journal-title":"Mol Cancer Ther"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1476-4598-9-122","volume":"9","author":"V Ganapathy","year":"2010","unstructured":"Ganapathy V, Ge R, Grazioli A et al (2010) Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9:122","journal-title":"Mol Cancer"},{"issue":"4","key":"12_CR29","first-page":"437","volume":"7","author":"J Singh","year":"2004","unstructured":"Singh J, Ling LE, Sawyer JS et al (2004) Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). Curr Opin Drug Discov Devel 7(4):437\u2013445","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"3","key":"12_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10555-006-9006-2","volume":"25","author":"SB Jakowlew","year":"2006","unstructured":"Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25(3):435\u2013457","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"12_CR31","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1182\/blood-2007-10-120337","volume":"111","author":"M Oka","year":"2008","unstructured":"Oka M, Iwata C, Suzuki HI et al (2008) Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood 111(9):4571\u20134579","journal-title":"Blood"},{"issue":"3","key":"12_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1124\/mol.65.3.744","volume":"65","author":"BS DaCosta","year":"2004","unstructured":"DaCosta BS, Major C, Laping NJ et al (2004) SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65(3):744\u2013752","journal-title":"Mol Pharmacol"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1186\/1471-2407-10-659","volume":"10","author":"S Suzuki","year":"2010","unstructured":"Suzuki S, Dobashi Y, Hatakeyama Y et al (2010) Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer 10:659","journal-title":"BMC Cancer"},{"issue":"3","key":"12_CR34","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ajpath.2011.11.021","volume":"180","author":"MK Conley-LaComb","year":"2012","unstructured":"Conley-LaComb MK, Huang W, Wang S et al (2012) PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 180(3):1017\u20131027","journal-title":"Am J Pathol"},{"issue":"2","key":"12_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/annonc\/mdp296","volume":"21","author":"T Donnem","year":"2010","unstructured":"Donnem T, Al-Saad S, Al-Shibli K et al (2010) Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 21(2):223\u2013231","journal-title":"Ann Oncol"},{"issue":"4","key":"12_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0002-9440(10)65229-7","volume":"155","author":"A Chott","year":"1999","unstructured":"Chott A, Sun Z, Morganstern D et al (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155(4):1271\u20131279","journal-title":"Am J Pathol"},{"issue":"1","key":"12_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ijc.23903","volume":"124","author":"T Hiraga","year":"2009","unstructured":"Hiraga T, Nakamura H (2009) Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int J Cancer 124(1):215\u2013222","journal-title":"Int J Cancer"},{"issue":"19","key":"12_CR38","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","volume":"13","author":"P Mathew","year":"2007","unstructured":"Mathew P, Thall PF, Bucana CD et al (2007) Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816\u20135824","journal-title":"Clin Cancer Res"},{"issue":"3","key":"12_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1359\/jbmr.090830","volume":"25","author":"RA Hannon","year":"2010","unstructured":"Hannon RA, Clack G, Rimmer M et al (2010) Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25(3):463\u2013471","journal-title":"J Bone Miner Res"},{"issue":"4","key":"12_CR40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bone.2011.12.017","volume":"50","author":"RA Hannon","year":"2012","unstructured":"Hannon RA, Finkelman RD, Clack G et al (2012) Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. Bone 50(4):885\u2013892","journal-title":"Bone"},{"issue":"1","key":"12_CR41","first-page":"249","volume":"31","author":"MG Fury","year":"2011","unstructured":"Fury MG, Baxi S, Shen R et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249\u2013253","journal-title":"Anticancer Res"},{"issue":"5","key":"12_CR42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","volume":"11","author":"A Gucalp","year":"2011","unstructured":"Gucalp A, Sparano JA, Caravelli J et al (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 11(5):306\u2013311","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"12_CR43","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s10637-011-9650-4","volume":"30","author":"HJ Mackay","year":"2012","unstructured":"Mackay HJ, Au HJ, McWhirter E et al (2012) A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs 30(3):1158\u20131163","journal-title":"Invest New Drugs"},{"issue":"11","key":"12_CR44","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/bjc.2012.158","volume":"106","author":"S Kaye","year":"2012","unstructured":"Kaye S, Aamdal S, Jones R et al (2012) Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours. Br J Cancer 106(11):1728\u20131734","journal-title":"Br J Cancer"},{"issue":"20","key":"12_CR45","doi-asserted-by":"publisher","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","volume":"65","author":"S Nam","year":"2005","unstructured":"Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20):9185\u20139189","journal-title":"Cancer Res"},{"issue":"2","key":"12_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10585-011-9436-2","volume":"29","author":"L Rice","year":"2012","unstructured":"Rice L, Lepler S, Pampo C et al (2012) Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis 29(2):133\u2013142","journal-title":"Clin Exp Metastasis"},{"issue":"13","key":"12_CR47","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1158\/1078-0432.CCR-11-3359","volume":"18","author":"CM Chan","year":"2012","unstructured":"Chan CM, Jing X, Pike LA et al (2012) Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res 18(13):3580\u20133591","journal-title":"Clin Cancer Res"},{"issue":"23","key":"12_CR48","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","volume":"15","author":"EY Yu","year":"2009","unstructured":"Yu EY, Wilding G, Posadas E et al (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15(23):7421\u20137428","journal-title":"Clin Cancer Res"},{"issue":"1","key":"12_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cncr.26204","volume":"118","author":"JC Araujo","year":"2012","unstructured":"Araujo JC, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1\u20132 study. Cancer 118(1):63\u201371","journal-title":"Cancer"},{"key":"12_CR50","doi-asserted-by":"crossref","unstructured":"Araujo JC, Trudel GC, Saad F et al (2013) Overall survival (OS) and safety of dasatinib\/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. J Clin Oncol 31(suppl 6; abstr LBA8). http:\/\/meetinglibrary.asco.org\/content\/106127-134","DOI":"10.1200\/jco.2013.31.6_suppl.lba8"},{"issue":"10","key":"12_CR51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrc1949","volume":"6","author":"MM Mohamed","year":"2006","unstructured":"Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6(10):764\u2013775","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"12_CR52","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/onc.2012.166","volume":"32","author":"MK Herroon","year":"2012","unstructured":"Herroon MK, Rajagurubandara E, Rudy DL et al (2012) Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene. 32(12):1580\u20131593. doi:10.1038\/onc.2012.166. Accessed 21 Mar 20132.","journal-title":"Oncogene."},{"issue":"2","key":"12_CR53","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ et al (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26(2):242\u2013251","journal-title":"J Bone Miner Res"},{"issue":"5","key":"12_CR54","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-11-2759","volume":"72","author":"NP Withana","year":"2012","unstructured":"Withana NP, Blum G, Sameni M et al (2012) Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 72(5):1199\u20131209","journal-title":"Cancer Res"},{"key":"12_CR55","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00691899. Accessed 21 Nov 2012"},{"key":"12_CR56","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00692458. Accessed 21 Nov 2012"},{"issue":"9","key":"12_CR57","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/cncr.23864","volume":"113","author":"JB Nelson","year":"2008","unstructured":"Nelson JB, Love W, Chin JL et al (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113(9):2478\u20132487","journal-title":"Cancer"},{"issue":"9","key":"12_CR58","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/cncr.22996","volume":"110","author":"MA Carducci","year":"2007","unstructured":"Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110(9):1959\u20131966","journal-title":"Cancer"},{"key":"12_CR59","doi-asserted-by":"crossref","unstructured":"Quinn DI, Tangen CM, Hussain M et al (2012) SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). J Clin Oncol 30 (suppl):abstr 4511. http:\/\/meetinglibrary.asco.org\/content\/99398-114","DOI":"10.1200\/jco.2012.30.15_suppl.4511"},{"issue":"22","key":"12_CR60","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1002\/cncr.27674","volume":"118","author":"JB Nelson","year":"2012","unstructured":"Nelson JB, Fizazi K, Miller K et al (2012) Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118(22):5709\u20135718","journal-title":"Cancer"},{"key":"12_CR61","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00626548. Accessed 21 Nov 2012"},{"key":"12_CR62","unstructured":"http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00617669. Accessed 21 Nov 2012"},{"key":"12_CR63","unstructured":"http:\/\/www.astrazeneca.com\/cs\/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DNarrativepdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285625798907&ssbinary=true. Accessed 21 Nov 2012"},{"issue":"2","key":"12_CR64","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T et al (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473(2):161\u2013164","journal-title":"FEBS Lett"},{"issue":"12","key":"12_CR65","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298\u20132308","journal-title":"Mol Cancer Ther"},{"key":"12_CR66","doi-asserted-by":"crossref","unstructured":"Smith MR, Sweeney C, Rathkopf DE et al (2012) Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol 30 (suppl):abstr 4513. http:\/\/meetinglibrary.asco.org\/content\/97353-114","DOI":"10.1200\/jco.2012.30.15_suppl.4513"},{"key":"12_CR67","doi-asserted-by":"crossref","unstructured":"Winer EP, Tolaney S, Nechushtan H et al (2012) Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30 (suppl):abstr 535. http:\/\/meetinglibrary.asco.org\/content\/95393-114","DOI":"10.1200\/jco.2012.30.15_suppl.535"},{"key":"12_CR68","doi-asserted-by":"crossref","unstructured":"Gordon MS, Kluger HM, Shapiro G et al (2012) Activity of cabozantinib (XL184) in metastatic melanoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30 (suppl):abstr 8531. http:\/\/meetinglibrary.asco.org\/content\/94473-114","DOI":"10.1200\/jco.2012.30.15_suppl.8531"},{"key":"12_CR69","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Pal SK, McDermott DF et al (2012) Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 30 (suppl):abstr 4504. http:\/\/meetinglibrary.asco.org\/content\/95382-114","DOI":"10.1200\/jco.2012.30.15_suppl.4504"},{"key":"12_CR70","doi-asserted-by":"crossref","unstructured":"Hellerstedt BA, Edelman G, Vogelzang NJ et al (2012) Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30 (suppl):abstr 7514. http:\/\/meetinglibrary.asco.org\/content\/95281-114","DOI":"10.1200\/jco.2012.30.15_suppl.7514"},{"key":"12_CR71","unstructured":"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm330143.htm. Accessed 5 Dec 2012"},{"issue":"10","key":"12_CR72","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603\u20131610","journal-title":"J Clin Oncol"},{"issue":"6","key":"12_CR73","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529","journal-title":"N Engl J Med"},{"issue":"10","key":"12_CR74","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","volume":"10","author":"H Glantschnig","year":"2003","unstructured":"Glantschnig H, Fisher JE, Wesolowski G et al (2003) M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase. Cell Death Differ 10(10):1165\u20131177","journal-title":"Cell Death Differ"},{"key":"12_CR75","doi-asserted-by":"crossref","unstructured":"Gnant M, Baselga J, Rugo HS et al (2012) Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). J Clin Oncol 30 (15_suppl):abstr 512 (May 20 Supplement)","DOI":"10.1200\/jco.2012.30.15_suppl.512"},{"key":"12_CR76","doi-asserted-by":"crossref","unstructured":"Maass N, Harbeck N, Mundhenke C et al (2012) Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: results of the phase II RADAR study. J Clin Oncol 30 (suppl):abstr 556. http:\/\/meetinglibrary.asco.org\/content\/95149-114","DOI":"10.1200\/jco.2012.30.15_suppl.556"}],"container-title":["Cancer Metastasis - Biology and Treatment","Bone Metastases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-94-007-7569-5_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T17:39:36Z","timestamp":1676828376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-94-007-7569-5_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,11]]},"ISBN":["9789400775688","9789400775695"],"references-count":76,"URL":"https:\/\/doi.org\/10.1007\/978-94-007-7569-5_12","relation":{},"ISSN":["1568-2102"],"issn-type":[{"type":"print","value":"1568-2102"}],"subject":[],"published":{"date-parts":[[2013,10,11]]},"assertion":[{"value":"11 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}